Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

Trevi Therapeutics, Inc. (TRVI) closed the last trading session at $6.41, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 21.22 indicates a 231.1% upside potential.The average comprises nine short-term price targets ranging from a low of $13.00 to a high of$ 29.00, with a standard deviation of $4.92. While the lowest estimate indicates an increase of 102.8% from the c ...